Trial Profile
A Randomized, Multicenter, Double-Blind, Placebo-Controlled Study of AC607 for the Treatment of Acute Kidney Injury in Cardiac Surgery Subjects
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 13 Aug 2014
Price :
$35
*
At a glance
- Drugs AC 607 (Primary)
- Indications Acute kidney injury
- Focus Therapeutic Use
- Acronyms ACT-AKI
- Sponsors AlloCure
- 05 Aug 2014 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
- 14 May 2014 New trial record